More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection 1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; ...
The Food and Drug Administration approved the Roche cobas HPV Test to detect human papilloma virus through the use of cervical cells collected for a Pap test and stored in SurePath Preservative Fluid.
New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...
Roche Diagnostics is looking to a new screening tool to help women learn in a more private way if they are at increased risk for cervical cancer—a self-collection test to identify HPV. With the test, ...
(RTTNews) - Biopharmaceutical company Roche Holding AG (RHHBY), announced on Tuesday that its cobas HPV test for use on the cobas 6800/8800 Systems has been awarded the World Health Organization (WHO) ...
Basel, 16 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the launch of a human papillomavirus (HPV) self sampling solution in countries accepting the CE mark. This new solution enables ...
The FDA approved a new self-collection test to detect human papillomavirus (HPV) and identify women at risk for cervical cancer, maker Roche announced on Wednesday. "HPV self-collection offers an ...
The U.S. Food and Drug Administration’s Medical Devices Advisory Committee Microbiology Panel unanimously voted that Roche Molecular Systems’ cobas viral DNA test is safe and effective as a ...
The HPV self-collection solution allows an individual to collect their own vaginal sample for HPV screening while at a health care facility. The Food and Drug Administration (FDA) has approved Roche’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback